(MENAFN- Kuwait News Agency (KUNA)) BRUSSELS, March 30 (KUNA) - The European Medicines Agency (EMA) Thursday recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA) as a booster in people aged 16 years and above who have been vaccinated with an mRNA COVID-19 vaccine.
Bimervax, developed by HIPRA Human Health, a multinational company based in Spain, contains a protein produced in the laboratory that consists of part of the SARS-CoV-2 spike protein from the Alpha and Beta virus variants, it said in a press release.
EMA concluded that a booster dose of Bimervax is expected to be at least as effective as Comirnaty at restoring protection against COVID-19 in people aged 16 years and older
It added that the benefits of Bimervax outweigh its risks and recommended granting a standard marketing authorisation in the EU. (end)
nk.ibi
MENAFN30032023000071011013ID1105916245
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.